课题基金 / 基金详情

MECHANISMS OF HER2 HETERODIMERIZATION

MECHANISMS OF HER2 HETERODIMERIZATION
HER2 异二聚化机制
批准号:
8816051
负责人:
RON BOSE
金额:
$31.54万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-03-01 至 2016-02-29

项目摘要

项目成果

RON BOSE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Her2 is a receptor tyrosine kinase and cellular proto-oncogene that plays a major role in breast and other human cancers. Her2 is a member of the ErbB - epidermal growth factor receptor (EGFR) family. Under physiologic conditions, Her2 functions by heterodimerizing with EGFR, Her3 or Her4 and then activating its tyrosine kinase. We developed a reconstituted in vitro system to study the heterodimerization and enzyme activation of Her2. We will study the structure of Her2 heterodimers using two mass spectrometry (MS) approaches, termed chemical footprinting MS, and we will combine this with molecular dynamics simulations to obtain atom level interpretations of the MS results. Conclusions from MS and molecular dynamics will be functionally tested using Fluorescence Resonance Energy Transfer (FRET) experiments and mutagenesis experiments in cell lines. This proposal will produce a sustained, powerful influence by producing a number of scientific "firsts", chief among them is the first structural study of a Her2-Her3 heterodimer. Her2-Her3 heterodimers form a very potent signaling pair and it is has been shown that knocking down Her3 in Her2- positive breast cancer cell lines reverses oncogenic transformation. Achieving the aims of this project will advance scientific knowledge by providing new structural and functional information on Her2-Her3 and EGFR-Her2 heterodimers. Achieving the aims of this project will also advance clinical practice by identifying which Her2 and Her3 cancer associated mutations likely drive cancer cell growth and are sensitive to Her2 targeted drugs. This information will identify new patients who are likely to benefit from Her2 targeted drugs and will provide the key scientific findings to support a future breast cancer clinical trial.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MECHANISMS OF HER2 HETERODIMERIZATION
  • 批准号:
    8625276
  • 项目类别:
  • 资助金额:
    $30.59万
  • 财政年份:
    2013
  • 负责人:
    RON BOSE
  • 依托单位:
MECHANISMS OF HER2 HETERODIMERIZATION
  • 批准号:
    8439379
  • 项目类别:
  • 资助金额:
    $31.54万
  • 财政年份:
    2013
  • 负责人:
    RON BOSE
  • 依托单位:
ACTIVATION AND REGULATION OF THE HER2 AND HER4 KINASES
  • 批准号:
    8361419
  • 项目类别:
  • 资助金额:
    $4.36万
  • 财政年份:
    2011
  • 负责人:
    RON BOSE
  • 依托单位:
PROTEIN QUANTIFICATION FOR MOUSE MODEL OF BREAST CANCER
  • 批准号:
    8361420
  • 项目类别:
  • 资助金额:
    $1.42万
  • 财政年份:
    2011
  • 负责人:
    RON BOSE
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: